Capricor Therapeutics Inc (CAPR)
PHARMACEUTICAL PREPARATIONS
Capricor Therapeutics Inc (CAPR) is listed on Nasdaq, where it has traded since June 20, 2002.
- Listed On
- Nasdaq
- Listed Since
- June 20, 2002
- Employees
- 231
- Market Cap
- $362M
About Capricor Therapeutics Inc
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 163 institutions reported holding CAPR, with 39.3 million shares worth $941.6 million in aggregate. The largest reported holder was BlackRock, with 4.1 million shares worth $99.8 million. Of the 5 largest holders listed below, all 5 added shares during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| BlackRock | 4,145,061 | $100M | Added 21.14% |
| Tang Capital Management | 4,099,900 | $99M | Added 20.59% |
| Suvretta Capital Management | 4,092,784 | $99M | Added 7.18% |
| State Street | 3,397,150 | $82M | Added 55.7% |
| Vanguard | 3,380,086 | $81M | Added 20.86% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is CAPR?
Capricor Therapeutics Inc (CAPR) is listed on Nasdaq, where it has traded since June 20, 2002.
Who are the largest institutional holders of CAPR?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of CAPR were BlackRock, Tang Capital Management and Suvretta Capital Management.
How many institutions own CAPR?
163 institutions reported a position in CAPR for the quarter ended June 30, 2026, worth $941.6 million in total.
Did institutions buy or sell CAPR last quarter?
Of the 5 largest reported holders, all 5 added shares during the quarter. Every reported holder and its change is on the SentiSense ownership page for CAPR.
Every reported institutional holder, plus insider and congressional trades in CAPR, on SentiSense.